Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplants Events

Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL)

Bone Marrow Transplantation volume 40, pages 989–993 (2007)Cite this article

Abstract

Stem cell transplantation is increasingly used in the management of immunoglobulin light-chain amyloidosis (AL). It is considered the standard of care to administer growth factors to accelerate neutrophil recovery after transplantation. However, unique toxicities occur with growth factor use in patients with AL who receive a stem cell transplant. We report a cohort of patients who underwent transplantation without receiving posttransplantation growth factors. In total, 282 patients received a stem cell transplant. A neutrophil count of 500/μl was achieved in 50, 75 and 90% of patients at 14, 16 and 22 days, respectively. A platelet count of 20 000/μl was achieved in 50, 75 and 90% of patients at 14, 20 and 31 days, respectively. Non-staphylococcal bacteremia was detected in 16% of patients. The median hospital stay was 9 days. It is feasible and reasonable to withhold growth factor therapy after autologous stem cell transplantation in patients with AL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Jansen J, Hanks S, Thompson JM, Dugan MJ, Akard LP . Transplantation of hematopoietic stem cells from the peripheral blood. J Cell Mol Med 2005; 9: 37–50.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Gabrilove JL . An analysis of current neutropenia therapies, including pegfilgrastim. Clin Cornerstone 2006; 8 (Suppl 5): S19–S28.

    Article  PubMed  Google Scholar 

  3. Akard LP, Thompson JM, Dugan MJ, Wiemann M, Greenspan A, Hanks S et al. Matched-pair analysis of hematopoietic progenitor cell mobilization using G-CSF vs. cyclophosphamide, etoposide, and G-CSF: enhanced CD34 cell collections are not necessarily cost-effective. Biol Blood Marrow Transplant 1999; 5: 379–385.

    Article  CAS  PubMed  Google Scholar 

  4. Worel N, Schulenburg A, Mitterbauer M, Keil F, Rabitsch W, Kalhs P et al. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity. Wien Klin Wochenschr 2006; 118: 49–53.

    Article  PubMed  Google Scholar 

  5. Perotti C, Del Fante C, Viarengo G, Perlini S, Vezzoli M, Rodi G et al. Peripheral blood progenitor cell mobilization and collection in 42 patients with primary systemic amyloidosis. Transfusion 2005; 45: 1729–1734.

    Article  CAS  PubMed  Google Scholar 

  6. Leung N, Leung TR, Cha SS, Dispenzieri A, Lacy MQ, Gertz MA . Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood 2005; 106: 3353–3357; e-pub ahead of print 21 July 2005.

    Article  CAS  PubMed  Google Scholar 

  7. Dember LM, Sanchorawala V, Seldin DC, Wright DG, LaValley M, Berk JL et al. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease. Ann Intern Med 2001; 134: 746–753.

    Article  CAS  PubMed  Google Scholar 

  8. Oran B, Wright DG, Seldin DC, McAneny D, Skinner M, Sanchorawala V . Spontaneous rupture of the spleen in AL amyloidosis. Am J Hematol 2003; 74: 131–135.

    Article  CAS  PubMed  Google Scholar 

  9. Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant 2004; 33: 381–388.

    Article  CAS  PubMed  Google Scholar 

  10. Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001; 28: 637–642.

    Article  CAS  PubMed  Google Scholar 

  11. Burgstaler EA, Pineda AA, Winters JL . Hematopoietic progenitor cell large volume leukapheresis (LVL) on the Fenwal Amicus blood separator. J Clin Apher 2004; 19: 103–111.

    Article  PubMed  Google Scholar 

  12. Balducci L, Carreca I . The role of myelopoietic growth factors in managing cancer in the elderly. Drugs 2002; 62 (Suppl 1): 47–63.

    Article  CAS  PubMed  Google Scholar 

  13. Crawford J . Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy 2003; 23: 15S–19S.

    Article  CAS  PubMed  Google Scholar 

  14. Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, Finn KT et al. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 2005; 35: 567–575 [Erratum in: Bone Marrow Transplant 2005; 35: 635].

    Article  CAS  PubMed  Google Scholar 

  15. Tarella C, Castellino C, Locatelli F, Caracciolo D, Corradini P, Falda M et al. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 1998; 21: 401–407.

    Article  CAS  PubMed  Google Scholar 

  16. Klaus J, Herrmann D, Breitkreutz I, Hegenbart U, Mazitschek U, Egerer G et al. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol 2007; 78: 21–28.

    Article  PubMed  Google Scholar 

  17. Ketterer N, Espinouse D, Chomarat M, Dumontet C, Moullet I, Rieux C et al. Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. Am J Med 1999; 106: 191–197.

    Article  CAS  PubMed  Google Scholar 

  18. Reich G, Mapara MY, Reichardt P, Dorken B, Maschmeyer G . Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant 2001; 27: 525–529.

    Article  CAS  PubMed  Google Scholar 

  19. Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C, Aulitzky WE . Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 143–147.

    Article  CAS  PubMed  Google Scholar 

  20. Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998; 101: 766–769.

    Article  CAS  PubMed  Google Scholar 

  21. Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol 2004; 127: 543–551.

    Article  CAS  PubMed  Google Scholar 

  22. Ojeda E, Garcia-Bustos J, Agaudo MJ, Quevedo E, Arrieta R, Jimenez V et al. Is filgrastim as useless after peripheral blood stem cell transplantation for adults as it could be for children? Blood 1999; 93: 3565–3566.

    CAS  PubMed  Google Scholar 

  23. Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, et al, British Society of Blood and Marrow Transplantation. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol 2006; 134: 385–390; e-pub ahead of print 5 July 2006.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Editing, proofreading and reference verification were provided by the Section of Scientific Publications, Mayo Clinic.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA

    M A Gertz, M Q Lacy, A Dispenzieri, S R Hayman, S K Kumar & D A Gastineau

  2. Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA

    N Leung

Authors
  1. M A Gertz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Q Lacy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Dispenzieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S R Hayman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S K Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D A Gastineau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M A Gertz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gertz, M., Lacy, M., Dispenzieri, A. et al. Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL). Bone Marrow Transplant 40, 989–993 (2007). https://doi.org/10.1038/sj.bmt.1705848

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705848

Keywords

This article is cited by

Search

Advanced search

Quick links